SGYP Key Statistics, Chart & Performance
The current stock price of SGYP is 0.03 null. In the past month the price decreased by -90.32%. In the past year, price decreased by -98.62%.
About SGYP
Company Profile
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.
Company Info
SYNERGY PHARMACEUTICALS DEL
420 LEXINGTON AVENUE SUITE 2012
NEW YORK NY 10170
CEO: Troy Hamilton
Phone: 212-297-0020
SYNERGY PHARMACEUTICALS DEL / SGYP FAQ
Can you describe the business of SYNERGY PHARMACEUTICALS DEL?
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.
What is the stock price of SYNERGY PHARMACEUTICALS DEL today?
The current stock price of SGYP is 0.03 null. The price decreased by -52% in the last trading session.
Does SYNERGY PHARMACEUTICALS DEL pay dividends?
SGYP does not pay a dividend.
What is the ChartMill rating of SYNERGY PHARMACEUTICALS DEL stock?
SGYP has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is SYNERGY PHARMACEUTICALS DEL worth?
SYNERGY PHARMACEUTICALS DEL (SGYP) has a market capitalization of 7.44M null. This makes SGYP a Nano Cap stock.
Who owns SYNERGY PHARMACEUTICALS DEL?
You can find the ownership structure of SYNERGY PHARMACEUTICALS DEL (SGYP) on the Ownership tab.
SGYP Technical Analysis
SGYP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to SGYP. While SGYP is still in line with the averages on profitability rating, there are concerns on its financial health.
SGYP Financial Highlights
Over the last trailing twelve months SGYP reported a non-GAAP Earnings per Share(EPS) of -0.5900000000000001. The EPS increased by 49.14% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -332.11% | ||
| ROA | -165.36% | ||
| ROE | 142.67% | ||
| Debt/Equity | 0 |